- Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Dec 3, 2025 · businesswire.com
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern District of Texas that found Seagen Inc's U.S. Patent No. 10,808,039 (the '039 patent) not invalid (the Texas decision). In view of the reversal, the Federal Circuit vacated the Texas court's related infringement judgment and damages award against Daiichi Sankyo. In a separate decision, the Federal C.
- FEDERAL CIRCUIT COURT OF APPEALS VACATES INFRINGEMENT JUDGMENT AND DAMAGES AWARD IN DISPUTE BETWEEN DAIICHI SANKYO AND SEAGEN
Dec 3, 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ON DECEMBER 2, THE U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT (THE FEDERAL CIRCUIT) REVERSED A DECISION FROM THE U.S. DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS THAT FOUND SEAGEN INC'S U.S. PATENT NO. 10,808,039 (THE '039 PATENT) NOT INVALID (THE TEXAS DECISION). IN VIEW OF THE REVERSAL, THE FEDERAL CIRCUIT VACATED THE TEXAS COURT'S RELATED INFRINGEMENT JUDGMENT AND DAMAGES AWARD AGAINST DAIICHI SANKYO. IN A SEPARATE DECISION, THE FEDERAL C.
- Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Aug 1, 2025 · youtube.com
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
- President Trump demands drugmakers slash prices within 60 days
Aug 1, 2025 · youtube.com
CNBC's Joe Kernen reports on the latest news.
- Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
Mar 20, 2025 · globenewswire.com
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Metastatic Melanoma. Refractory Metastatic Melanoma Emerging Drugs Chapters This segment of the Refractory Metastatic Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Refractory Metastatic Melanoma Emerging Drugs
- REFRACTORY METASTATIC MELANOMA PIPELINE REPORT 2025, WITH FOCUS ON BIONTECH SE, Y-MABS AND THERAPEUTICS SEAGEN
Mar 20, 2025
DUBLIN, MARCH 20, 2025 (GLOBE NEWSWIRE) -- THE "REFRACTORY METASTATIC MELANOMA - PIPELINE INSIGHT, 2025" CLINICAL TRIALS HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THE REPORT PROVIDES COMPREHENSIVE INSIGHTS ABOUT 4+ COMPANIES AND 4+ PIPELINE DRUGS IN REFRACTORY METASTATIC MELANOMA PIPELINE LANDSCAPE. IT COVERS THE PIPELINE DRUG PROFILES, INCLUDING CLINICAL AND NONCLINICAL STAGE PRODUCTS. IT ALSO COVERS THE THERAPEUTICS ASSESSMENT BY PRODUCT TYPE, STAGE, ROUTE OF ADMINISTRATION, AND MOLECULE TYPE. IT FURTHER HIGHLIGHTS THE INACTIVE PIPELINE PRODUCTS IN THIS SPACE. REPORT HIGHLIGHTS THE COMPANIES AND ACADEMICS ARE WORKING TO ASSESS CHALLENGES AND SEEK OPPORTUNITIES THAT COULD INFLUENCE REFRACTORY METASTATIC MELANOMA R&D. THE THERAPIES UNDER DEVELOPMENT ARE FOCUSED ON NOVEL APPROACHES TO TREAT/IMPROVE REFRACTORY METASTATIC MELANOMA. REFRACTORY METASTATIC MELANOMA EMERGING DRUGS CHAPTERS THIS SEGMENT OF THE REFRACTORY METASTATIC MELANOMA REPORT ENCLOSES ITS DETAILED ANALYSIS OF VARIOUS DRUGS IN DIFFERENT STAGES OF CLINICAL DEVELOPMENT, INCLUDING PHASE III, II, I, PRECLINICAL AND DISCOVERY. IT ALSO HELPS TO UNDERSTAND CLINICAL TRIAL DETAILS, EXPRESSIVE PHARMACOLOGICAL ACTION, AGREEMENTS AND COLLABORATIONS, AND THE LATEST NEWS AND PRESS RELEASES. REFRACTORY METASTATIC MELANOMA EMERGING DRUGS
- Two Brothers, a Big Biotech Bet and an $8 Billion Payout
Apr 13, 2024 · wsj.com
Investors in a hedge fund from Baker Bros. Advisors recently received one of the largest windfalls ever following Pfizer's purchase of Seagen.
- Pfizer: Seagen Acquisition Starting To Bear Fruit
Mar 12, 2024 · seekingalpha.com
Pfizer's share price has stabilized since the company provided 2024 revenue and EPS guidance in late 2023. The success of Adcetris in a trial for relapsed/refractory DLBCL is a positive step for Pfizer's oncology pipeline and the first win since the Seagen acquisition closed. Pfizer's long-term growth strategy in oncology, including the Seagen acquisition, is expected to contribute significantly to revenue growth in the coming years.
- Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition
Mar 2, 2024 · geekwire.com
Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle near its headquarters.
- Cramer names biopharma companies to watch as industry mergers start to pile up
Jan 5, 2024 · cnbc.com
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.